~~<i id='AD982D1D10'><strike id='AD982D1D10'><tt id='AD982D1D10'><pre id='AD982D1D10'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：hotspot 2025-10-01 17:34:04 - browse：74273

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： 3 hurdles to bringing medical devices to the U.S. market

hotspot

explore

focus

leisure time

hotspot

explore

Fingernailssometimesfalloffwhenthey’redamaged—likeiftheygetstuckinacardoor.Thathastodowithwhat’sknow

WSS

How generative AI is inspiring dreams of a health data revolution

How generative AI is inspiring dreams of a health data revolution

What drug price negotiations mean for Medicare Part D

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

The battle over the Brookhaven Landfill on Long Island

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

focus

fashion

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

The strategy behind pharma's lawsuits over drug pricing reform

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ethical issues complicate the benefits of medical crowdfunding

State Dept. review finds Biden bears some blame for Afghanistan failures

How to fix cancer clinical trials' diversity problem

23andMe had bad news about my health. I wish a person had delivered it

Death of patient in Alzheimer’s trial raises question of possible risks

Cancer drug shortages should be causing more outrage

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

explore

Weighted lottery helped low

The science behind Janet Jackson's pregnancy at 49

Colonoscopy at 40? Study finds a possible benefit

'Make People Better': The CRISPR babies story you probably don't know

Stem cell treatment guidelines are released by FDA

NIH nominee Bertagnolli will get October confirmation hearing

focus

leisure time

hotspot

explore